Paramasivan C N, Chandrasekaran V, Santha T, Sudarsanam N M, Prabhakar R
Tuberculosis Research Centre, (Indian Council of Medical Research), Chetput, Madras, India.
Tuber Lung Dis. 1993 Feb;74(1):23-7. doi: 10.1016/0962-8479(93)90064-5.
To examine the bacteriological profile and the prevalence of drug resistance among patients attending the health facilities where the District Tuberculosis Programme (DTP) was in operation with short-course chemotherapy (SCC) regimens, sputum specimens were collected on admission and the end of treatment in North Arcot district and Pondicherry region. In North Arcot district, rifampicin, isoniazid and pyrazinamide were given twice weekly for the first 2 months followed by rifampicin and isoniazid twice a week for the next 4 months under fully supervised administration. In Pondicherry, rifampicin, isoniazid and pyrazinamide were given daily for the first 2 months followed by rifampicin and isoniazid twice weekly for the next 4 months. Of the patients who had received 80% or more of the drugs, 80% from North Arcot and 92% from Pondicherry were rendered culture-negative for Mycobacterium tuberculosis at the end of treatment. Even among patients with initially resistant bacilli, a high proportion had a favourable response. Before start of treatment, of the 2779 patients from North Arcot, 25% had resistance to one or more drugs including 2% with resistance to rifampicin. In Pondicherry, 13% of the patients had initial resistance to one or more drugs. Initial resistance to rifampicin was observed in 0.9%. None of the initially drug-sensitive patients had acquired resistance to rifampicin at the end of treatment.
为了调查在实施地区结核病规划(DTP)短程化疗(SCC)方案的医疗机构就诊患者的细菌学特征和耐药率,在北阿科特地区和本地治里地区,于患者入院时和治疗结束时采集痰标本。在北阿科特地区,利福平、异烟肼和吡嗪酰胺在前2个月每周给药两次,随后在完全监督管理下的接下来4个月中,利福平和异烟肼每周给药两次。在本地治里,利福平、异烟肼和吡嗪酰胺在前2个月每日给药,随后在接下来4个月中利福平和异烟肼每周给药两次。在接受了80%或更多药物治疗的患者中,北阿科特地区80%的患者和本地治里地区92%的患者在治疗结束时结核分枝杆菌培养转阴。即使在最初为耐药菌的患者中,也有很大比例有良好反应。在治疗开始前,北阿科特地区的2779例患者中,25%对一种或多种药物耐药,其中2%对利福平耐药。在本地治里,13%的患者对一种或多种药物初始耐药。利福平初始耐药率为0.9%。在治疗结束时,所有最初对药物敏感的患者均未获得对利福平的耐药性。